Cargando…

Efficacy and Safety of Daclatasvir in Hepatitis C: An Overview

Hepatitis C virus (HCV) infection is a growing public health concern, with 184 million people infected worldwide. During the past decade, interferon has been the backbone of HCV treatment, even though it remains far from ideal. The latest development of the new direct antivirals has drastically chan...

Descripción completa

Detalles Bibliográficos
Autores principales: Gamal, Nesrine, Gitto, Stefano, Andreone, Pietro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: XIA & HE Publishing Inc. 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225154/
https://www.ncbi.nlm.nih.gov/pubmed/28097103
http://dx.doi.org/10.14218/JCTH.2016.00038
_version_ 1782493463394123776
author Gamal, Nesrine
Gitto, Stefano
Andreone, Pietro
author_facet Gamal, Nesrine
Gitto, Stefano
Andreone, Pietro
author_sort Gamal, Nesrine
collection PubMed
description Hepatitis C virus (HCV) infection is a growing public health concern, with 184 million people infected worldwide. During the past decade, interferon has been the backbone of HCV treatment, even though it remains far from ideal. The latest development of the new direct antivirals has drastically changed the treatment approach for chronic hepatitis C (CHC). Inhibitors of the HCV NS5A region have garnered remarkable interest among treating physicians, due to their high potency and favourable safety profile. In particular, treatment with daclatasvir (DCV) has yielded high rates of vriologic response in patients infected with genotype (Gt) 1 and Gt 3, when used in combination with other antivirals of a different class, such as sofosbuvir. Although few data are available for DCV treatment of the other Gts, the results in patients with Gt 2 and Gt 4 infection appear promising, as do those for unique patient populations. NS5A-resistant viral variants can pre-exist or emerge after treatment failure for the HCV NS5A inhibitors. Nonetheless, DCV-resistant viral variants continue to be sensitive to interferon and other classes of antivirals such as NS3/4A and NS5B inhibitors. Herein, we aimed to provide an overview of the current knowledge about DCV in the treatment of CHC.
format Online
Article
Text
id pubmed-5225154
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher XIA & HE Publishing Inc.
record_format MEDLINE/PubMed
spelling pubmed-52251542017-01-17 Efficacy and Safety of Daclatasvir in Hepatitis C: An Overview Gamal, Nesrine Gitto, Stefano Andreone, Pietro J Clin Transl Hepatol Review Article Hepatitis C virus (HCV) infection is a growing public health concern, with 184 million people infected worldwide. During the past decade, interferon has been the backbone of HCV treatment, even though it remains far from ideal. The latest development of the new direct antivirals has drastically changed the treatment approach for chronic hepatitis C (CHC). Inhibitors of the HCV NS5A region have garnered remarkable interest among treating physicians, due to their high potency and favourable safety profile. In particular, treatment with daclatasvir (DCV) has yielded high rates of vriologic response in patients infected with genotype (Gt) 1 and Gt 3, when used in combination with other antivirals of a different class, such as sofosbuvir. Although few data are available for DCV treatment of the other Gts, the results in patients with Gt 2 and Gt 4 infection appear promising, as do those for unique patient populations. NS5A-resistant viral variants can pre-exist or emerge after treatment failure for the HCV NS5A inhibitors. Nonetheless, DCV-resistant viral variants continue to be sensitive to interferon and other classes of antivirals such as NS3/4A and NS5B inhibitors. Herein, we aimed to provide an overview of the current knowledge about DCV in the treatment of CHC. XIA & HE Publishing Inc. 2016-11-03 2016-12-28 /pmc/articles/PMC5225154/ /pubmed/28097103 http://dx.doi.org/10.14218/JCTH.2016.00038 Text en © 2016 The Second Affiliated Hospital of Chongqing Medical University. Published by XIA & HE Publishing Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 4.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Gamal, Nesrine
Gitto, Stefano
Andreone, Pietro
Efficacy and Safety of Daclatasvir in Hepatitis C: An Overview
title Efficacy and Safety of Daclatasvir in Hepatitis C: An Overview
title_full Efficacy and Safety of Daclatasvir in Hepatitis C: An Overview
title_fullStr Efficacy and Safety of Daclatasvir in Hepatitis C: An Overview
title_full_unstemmed Efficacy and Safety of Daclatasvir in Hepatitis C: An Overview
title_short Efficacy and Safety of Daclatasvir in Hepatitis C: An Overview
title_sort efficacy and safety of daclatasvir in hepatitis c: an overview
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5225154/
https://www.ncbi.nlm.nih.gov/pubmed/28097103
http://dx.doi.org/10.14218/JCTH.2016.00038
work_keys_str_mv AT gamalnesrine efficacyandsafetyofdaclatasvirinhepatitiscanoverview
AT gittostefano efficacyandsafetyofdaclatasvirinhepatitiscanoverview
AT andreonepietro efficacyandsafetyofdaclatasvirinhepatitiscanoverview